164 related articles for article (PubMed ID: 1624679)
1. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
Bromberg N; Romaldini JH; Werner RS; Sgarbi JA; Werner MC
J Endocrinol Invest; 1992 Mar; 15(3):191-5. PubMed ID: 1624679
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
4. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
8. Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.
Molnár I; Szentmiklósi JA; Gesztelyi R; Somogyiné-Vári É
Clin Exp Med; 2019 May; 19(2):245-254. PubMed ID: 30610492
[TBL] [Abstract][Full Text] [Related]
9. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
[TBL] [Abstract][Full Text] [Related]
10. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
[TBL] [Abstract][Full Text] [Related]
11. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
[TBL] [Abstract][Full Text] [Related]
14. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
15. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
16. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
17. Changes in thyrotropin binding inhibitor immunoglobulin (TBII) concentration before and after various treatments in a patient with infiltrative Graves' ophthalmopathy.
Mori T; Tanaka K; Akamizu T; Yokota T; Ishii H; Nakamura H; Imura H
Endocrinol Jpn; 1985 Apr; 32(2):327-36. PubMed ID: 2864242
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
19. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
20. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
